Trimebutine

Trimebutine
Trimebutine
Systematic (IUPAC) name
2-(Dimethylamino)-2-phenylbutyl 3,4,5-trimethoxybenzoate
Clinical data
AHFS/Drugs.com International Drug Names
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 39133-31-8
ATC code A03AA05
PubChem CID 5573
UNII QZ1OJ92E5R YesY
Chemical data
Formula C22H29NO5 
Mol. mass 387.47 g/mol
 YesY(what is this?)  (verify)

Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects.[1] The maleic acid salt of trimebutine is marketed under the trademark of Debridat, Recutin, Polybutin,[2] or Modulon for treatment of irritable bowel syndrome and other gastrointestinal disorders. The major product from drug metabolism of trimebutine in human beings is nor-trimebutine,[3] which comes from removal of one of the methyl groups attached to nitrogen. Both Trimebutine and its metabolite are commercially available.

References

  1. ^ Kaneto H, Takahashi M, Watanabe J. The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. Journal of Pharmacobiodynamics. 1990 Jul;13(7):448-53. PMID 1963196
  2. ^ Ok Hwa Jhee, Yun Sik Lee, Leslie M. Shaw, Yong Cheol Jeon, Min Ho Lee, Seung Hoon Lee and Ju Seop Kang The Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC–MS/MS method. Clinica Chimica Acta. 2007 Jan;375(1-2):69-75. PMID 16854404
  3. ^ F.J. Roman, S. Lanet, J. Hamon, G. Brunelle, A. Maurin, P. Champeroux, S. Richard, N. Alessandri, and M. Gola Pharmacological Properties of Trimebutine and N-Monodesmethyltrimebutine. The Journal of Pharmacology and Experimental Therapeutics 1999;289:1391–1397. PMID 10336531